PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trialFlorian Lordick, J. R. Siewert, Christian Peschel et al.|The Lancet Oncology|2007Cited by 808
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah‐Eddin Al‐Batran, Andrea Tannapfel, Ralf‐Dieter Hofheinz et al.|The Lancet Oncology|2016Cited by 738
Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieSylvie Lorenzen, Florian Lordick, Tibor Schuster et al.|Annals of Oncology|2009Cited by 241
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGISalah‐Eddin Al‐Batran, Stefan Paul Moenig, Thorsten Oliver Goetze et al.|BMC Cancer|2017Cited by 226
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialSylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss‐Patience et al.|Journal of Clinical Oncology|2023Cited by 192